This company has been marked as potentially delisted and may not be actively trading.

Apellis Pharmaceuticals (APLS) Competitors

APLS vs. VTRS, MRNA, GMAB, ASND, and SMMT

Should you buy Apellis Pharmaceuticals stock or one of its competitors? MarketBeat compares Apellis Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Apellis Pharmaceuticals include Viatris (VTRS), Moderna (MRNA), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Apellis Pharmaceuticals compare to Viatris?

Viatris (NASDAQ:VTRS) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

In the previous week, Viatris had 3 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 3 mentions for Viatris and 0 mentions for Apellis Pharmaceuticals. Viatris' average media sentiment score of 0.54 beat Apellis Pharmaceuticals' score of 0.25 indicating that Viatris is being referred to more favorably in the media.

Company	Overall Sentiment
Viatris	Positive
Apellis Pharmaceuticals	Neutral

Viatris presently has a consensus price target of $17.50, indicating a potential upside of 10.20%. Apellis Pharmaceuticals has a consensus price target of $35.72, indicating a potential downside of 12.94%. Given Viatris' stronger consensus rating and higher probable upside, research analysts plainly believe Viatris is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Viatris has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Viatris' net margin of -2.04%. Apellis Pharmaceuticals' return on equity of 39.71% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

Apellis Pharmaceuticals has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.29	-$3.51B	-$0.26	N/A
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23

Summary

Apellis Pharmaceuticals beats Viatris on 9 of the 16 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Moderna?

Moderna (NASDAQ:MRNA) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations, dividends and media sentiment.

Moderna currently has a consensus price target of $35.73, indicating a potential downside of 24.68%. Apellis Pharmaceuticals has a consensus price target of $35.72, indicating a potential downside of 12.94%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Apellis Pharmaceuticals has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	9.68	-$2.82B	-$8.15	N/A
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23

In the previous week, Moderna had 31 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 31 mentions for Moderna and 0 mentions for Apellis Pharmaceuticals. Moderna's average media sentiment score of 0.48 beat Apellis Pharmaceuticals' score of 0.25 indicating that Moderna is being referred to more favorably in the media.

Company	Overall Sentiment
Moderna	Neutral
Apellis Pharmaceuticals	Neutral

Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market.

75.3% of Moderna shares are owned by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. 10.8% of Moderna shares are owned by company insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Apellis Pharmaceuticals has a net margin of 12.06% compared to Moderna's net margin of -143.55%. Apellis Pharmaceuticals' return on equity of 39.71% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

Summary

Apellis Pharmaceuticals beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Genmab A/S?

Apellis Pharmaceuticals (NASDAQ:APLS) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Apellis Pharmaceuticals has a beta of -0.24, suggesting that its share price is 124% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Genmab A/S had 2 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 2 mentions for Genmab A/S and 0 mentions for Apellis Pharmaceuticals. Genmab A/S's average media sentiment score of 0.71 beat Apellis Pharmaceuticals' score of 0.25 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Apellis Pharmaceuticals	Neutral
Genmab A/S	Positive

96.3% of Apellis Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 6.5% of Apellis Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Apellis Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23
Genmab A/S	$3.72B	4.22	$963M	$1.32	19.05

Genmab A/S has a net margin of 21.05% compared to Apellis Pharmaceuticals' net margin of 12.06%. Apellis Pharmaceuticals' return on equity of 39.71% beat Genmab A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
Genmab A/S	21.05%	15.34%	8.94%

Apellis Pharmaceuticals presently has a consensus price target of $35.72, suggesting a potential downside of 12.94%. Genmab A/S has a consensus price target of $37.93, suggesting a potential upside of 50.81%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Genmab A/S beats Apellis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Ascendis Pharma A/S?

Apellis Pharmaceuticals (NASDAQ:APLS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Apellis Pharmaceuticals has a beta of -0.24, suggesting that its stock price is 124% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Ascendis Pharma A/S has a net margin of 57.87% compared to Apellis Pharmaceuticals' net margin of 12.06%. Apellis Pharmaceuticals' return on equity of 39.71% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apellis Pharmaceuticals	12.06%	39.71%	13.20%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Apellis Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23
Ascendis Pharma A/S	$814.57M	16.12	-$258M	$8.67	24.27

96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Ascendis Pharma A/S had 7 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 0 mentions for Apellis Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 1.13 beat Apellis Pharmaceuticals' score of 0.25 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Apellis Pharmaceuticals	Neutral
Ascendis Pharma A/S	Positive

Apellis Pharmaceuticals currently has a consensus price target of $35.72, suggesting a potential downside of 12.94%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 40.36%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats Apellis Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Apellis Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Summit Therapeutics currently has a consensus price target of $26.05, suggesting a potential upside of 76.40%. Apellis Pharmaceuticals has a consensus price target of $35.72, suggesting a potential downside of 12.94%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Summit Therapeutics is more favorable than Apellis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Apellis Pharmaceuticals	1 Sell rating(s)	18 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09

Apellis Pharmaceuticals has a net margin of 12.06% compared to Summit Therapeutics' net margin of 0.00%. Apellis Pharmaceuticals' return on equity of 39.71% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Apellis Pharmaceuticals	12.06%	39.71%	13.20%

In the previous week, Summit Therapeutics had 17 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 17 mentions for Summit Therapeutics and 0 mentions for Apellis Pharmaceuticals. Summit Therapeutics' average media sentiment score of 0.50 beat Apellis Pharmaceuticals' score of 0.25 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Summit Therapeutics	Positive
Apellis Pharmaceuticals	Neutral

Summit Therapeutics has a beta of -1.32, indicating that its stock price is 232% less volatile than the broader market. Comparatively, Apellis Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

Apellis Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Apellis Pharmaceuticals	$1.11B	4.75	$22.39M	$1.02	40.23

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Apellis Pharmaceuticals beats Summit Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Apellis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLS vs. The Competition

Export

Metric	Apellis Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.25B	$3.34B	$6.68B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	40.23	18.69	24.01	23.62
Price / Sales	4.75	300.34	519.33	112.45
Price / Cash	196.33	116.33	42.23	54.60
Price / Book	12.66	6.51	9.73	6.35
Net Income	$22.39M	$24.19M	$3.57B	$337.59M

Apellis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLS Apellis Pharmaceuticals	1.4063 of 5 stars	$41.03 flat	$35.72 -12.9%	+114.8%	$5.25B	$1.11B	40.23	770	High Trading Volume
VTRS Viatris	3.241 of 5 stars	$15.81 -2.8%	$16.43 +3.9%	+87.7%	$18.94B	$14.30B	N/A	30,000
MRNA Moderna	1.5423 of 5 stars	$46.06 -2.4%	$35.73 -22.4%	+81.6%	$18.72B	$1.94B	N/A	4,700
GMAB Genmab A/S	4.1983 of 5 stars	$25.45 -3.3%	$37.93 +49.0%	+15.3%	$16.42B	$3.72B	19.28	3,029	Gap Down
ASND Ascendis Pharma A/S	4.6371 of 5 stars	$218.82 -2.4%	$295.39 +35.0%	+18.5%	$13.98B	$865.78M	25.24	1,189	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLS) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apellis Pharmaceuticals (APLS) Competitors

APLS vs. VTRS, MRNA, GMAB, ASND, and SMMT

How does Apellis Pharmaceuticals compare to Viatris?

Summary

How does Apellis Pharmaceuticals compare to Moderna?

Summary

How does Apellis Pharmaceuticals compare to Genmab A/S?

Summary

How does Apellis Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Apellis Pharmaceuticals compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS vs. The Competition

Apellis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apellis Pharmaceuticals (APLS) Competitors

APLS vs. VTRS, MRNA, GMAB, ASND, and SMMT

How does Apellis Pharmaceuticals compare to Viatris?

Does the media prefer VTRS or APLS?

Do analysts prefer VTRS or APLS?

Which has more risk and volatility, VTRS or APLS?

Do institutionals and insiders have more ownership in VTRS or APLS?

Is VTRS or APLS more profitable?

Which has higher valuation & earnings, VTRS or APLS?

Summary

How does Apellis Pharmaceuticals compare to Moderna?

Do analysts recommend MRNA or APLS?

Which has higher earnings & valuation, MRNA or APLS?

Does the media prefer MRNA or APLS?

Which has more volatility & risk, MRNA or APLS?

Do institutionals & insiders have more ownership in MRNA or APLS?

Is MRNA or APLS more profitable?

Summary

How does Apellis Pharmaceuticals compare to Genmab A/S?

Which has more volatility & risk, APLS or GMAB?

Does the media favor APLS or GMAB?

Do institutionals and insiders have more ownership in APLS or GMAB?

Which has stronger valuation and earnings, APLS or GMAB?

Is APLS or GMAB more profitable?

Do analysts rate APLS or GMAB?

Summary

How does Apellis Pharmaceuticals compare to Ascendis Pharma A/S?

Which has more risk and volatility, APLS or ASND?

Is APLS or ASND more profitable?

Which has better valuation & earnings, APLS or ASND?

Do insiders and institutionals have more ownership in APLS or ASND?

Does the media favor APLS or ASND?

Do analysts rate APLS or ASND?

Summary

How does Apellis Pharmaceuticals compare to Summit Therapeutics?

Do analysts recommend SMMT or APLS?

Is SMMT or APLS more profitable?

Does the media refer more to SMMT or APLS?

Which has more volatility & risk, SMMT or APLS?

Which has preferable earnings & valuation, SMMT or APLS?

Do institutionals & insiders hold more shares of SMMT or APLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS vs. The Competition

Apellis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools